|
Alzheimer disease, familial, type 3
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
CMT type 2U (CMT2U) is an autosomal dominant (AD) disease caused by mutations in the MARS gene encoding methionyl-tRNA synthetase; this disease has thus been newly called AD-CMTax-MARS.
|
27717217 |
2016 |
|
Alzheimer's Disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
CMT type 2U (CMT2U) is an autosomal dominant (AD) disease caused by mutations in the MARS gene encoding methionyl-tRNA synthetase; this disease has thus been newly called AD-CMTax-MARS.
|
27717217 |
2016 |
|
Cerebrovascular accident
|
0.010 |
Biomarker
|
group |
BEFREE |
The MARS-5 is a feasible and valid self-assessed medication adherence for older patients with stroke.
|
29649015 |
2019 |
|
Charcot-Marie-Tooth Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
Histopathological features of a patient with Charcot-Marie-Tooth disease type 2U/AD-CMTax-MARS.
|
27717217 |
2016 |
|
Charcot-Marie-Tooth Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our findings underscore the phenotypic variability associated with ARS mutations, and suggest genetic or environmental modifying factors in the onset of monoallelic MARS-associated CMT2.
|
29655802 |
2018 |
|
CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2U
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Whole-exome sequencing reveals a novel missense mutation in the MARS gene related to a rare Charcot-Marie-Tooth neuropathy type 2U.
|
29582526 |
2018 |
|
Depressed mood
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
A meta-analysis was performed on data from three genome-wide pharmacogenetic studies (the Genome-Based Therapeutic Drugs for Depression [GENDEP] project, the Munich Antidepressant Response Signature [MARS] project, and the Sequenced Treatment Alternatives to Relieve Depression [STAR*D] study), which included 2,256 individuals of Northern European descent with major depressive disorder, and antidepressant treatment outcomes were prospectively collected.
|
23377640 |
2013 |
|
Depressed mood
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Instruments used at baseline and during a six-month follow-up period were the following: disease-specific self-efficacy (Epilepsy Self-Efficacy Scale [ESES], General Self-Efficacy Scale [GSES]); adherence (Medication Adherence Scale [MARS] and Medication Event Monitoring System [MEMS]); seizure severity (National Hospital Seizure Severity Scale [NHS3]); emotional well-being (Hospital Anxiety and Depression Scale [HADS]); quality of life (Quality of Life in Epilepsy [QOLIE-31P]); proactive coping (Utrecht Proactive Coping Competence [UPCC]); and side-effects of antiepileptic drugs [SIDAED].
|
29449140 |
2018 |
|
Depressed mood
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Stroke patients older than 65 years (N = 523) filled out the MARS-5 and the Hospital Anxiety and Depression Scale.
|
29649015 |
2019 |
|
Depressed mood
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
We analyzed data from an observational MDD cohort (Munich Antidepressant Response Signature [MARS] study, N = 1017), treated individually by psychopharmacological and psychotherapeutic means, and a multicenter, partially randomized clinical/pharmacogenomic study (Genome-based Therapeutic Drugs for Depression [GENDEP], N = 809).
|
31383853 |
2019 |
|
Depressive disorder
|
0.040 |
Biomarker
|
disease |
BEFREE |
We analyzed data from an observational MDD cohort (Munich Antidepressant Response Signature [MARS] study, N = 1017), treated individually by psychopharmacological and psychotherapeutic means, and a multicenter, partially randomized clinical/pharmacogenomic study (Genome-based Therapeutic Drugs for Depression [GENDEP], N = 809).
|
31383853 |
2019 |
|
Depressive disorder
|
0.040 |
Biomarker
|
disease |
BEFREE |
A meta-analysis was performed on data from three genome-wide pharmacogenetic studies (the Genome-Based Therapeutic Drugs for Depression [GENDEP] project, the Munich Antidepressant Response Signature [MARS] project, and the Sequenced Treatment Alternatives to Relieve Depression [STAR*D] study), which included 2,256 individuals of Northern European descent with major depressive disorder, and antidepressant treatment outcomes were prospectively collected.
|
23377640 |
2013 |
|
Depressive disorder
|
0.040 |
Biomarker
|
disease |
BEFREE |
Stroke patients older than 65 years (N = 523) filled out the MARS-5 and the Hospital Anxiety and Depression Scale.
|
29649015 |
2019 |
|
Depressive disorder
|
0.040 |
Biomarker
|
disease |
BEFREE |
Instruments used at baseline and during a six-month follow-up period were the following: disease-specific self-efficacy (Epilepsy Self-Efficacy Scale [ESES], General Self-Efficacy Scale [GSES]); adherence (Medication Adherence Scale [MARS] and Medication Event Monitoring System [MEMS]); seizure severity (National Hospital Seizure Severity Scale [NHS3]); emotional well-being (Hospital Anxiety and Depression Scale [HADS]); quality of life (Quality of Life in Epilepsy [QOLIE-31P]); proactive coping (Utrecht Proactive Coping Competence [UPCC]); and side-effects of antiepileptic drugs [SIDAED].
|
29449140 |
2018 |
|
Encephalopathies
|
0.010 |
Biomarker
|
group |
BEFREE |
MARS therapy resulted in significant improvement in liver function, coagulation, incidence of encephalopathy, and creatinine.
|
28692474 |
2017 |
|
Epilepsy
|
0.020 |
Biomarker
|
disease |
BEFREE |
Eligible PWE (n=760) completed the religiosity scale (Duke University Religion Index; DUREL) at baseline; the religious coping scale (Brief Religious Coping Scale; Brief RCOPE) one month later; the medication adherence scale (Medication Adherence Report Scale; MARS-5) two months later; and the QoL scale (Quality of Life in Epilepsy; QOLIE-31) twelve months later.
|
29175219 |
2018 |
|
Epilepsy
|
0.020 |
Biomarker
|
disease |
BEFREE |
Instruments used at baseline and during a six-month follow-up period were the following: disease-specific self-efficacy (Epilepsy Self-Efficacy Scale [ESES], General Self-Efficacy Scale [GSES]); adherence (Medication Adherence Scale [MARS] and Medication Event Monitoring System [MEMS]); seizure severity (National Hospital Seizure Severity Scale [NHS3]); emotional well-being (Hospital Anxiety and Depression Scale [HADS]); quality of life (Quality of Life in Epilepsy [QOLIE-31P]); proactive coping (Utrecht Proactive Coping Competence [UPCC]); and side-effects of antiepileptic drugs [SIDAED].
|
29449140 |
2018 |
|
Hyperlipoproteinemia Type IIa
|
0.010 |
Biomarker
|
disease |
BEFREE |
A multidisciplinary group of FH experts, in collaboration with a sounding board of FH patients (n = 166), developed a health-related outcomes set containing the domains: medication adherence (MARS-5), smoking, self-efficacy and self-management, quality of life (QOL) (EQ-5D-5L), reported adverse drug reactions, lipid outcome measures, and FH and cardiovascular risk factor knowledge.Knowledge scores ranged from 0 to 10.
|
31821958 |
2020 |
|
INTERSTITIAL LUNG AND LIVER DISEASE
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Biallelic MARS mutations are associated with interstitial lung and liver disease (ILLD).
|
29655802 |
2018 |
|
Liver Failure
|
0.030 |
Biomarker
|
disease |
BEFREE |
MARS was used to support patients with severe liver trauma (SLT), in ALF patients as a bridge to transplantation (BTT), and as definitive therapy for toxic ingestion or idiopathic liver failure (DT) in a level 1 trauma center and large transplant center.
|
28692474 |
2017 |
|
Liver Failure
|
0.030 |
Biomarker
|
disease |
BEFREE |
A dynamic recirculation model for liver failure was used for upscaling and comparison against conventional MARS adsorbents as the gold standard in an albumin dialysis setting.
|
29266788 |
2018 |
|
Liver Failure
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
In paediatric liver failure, data on extracorporeal systems is scarce, comprising few reports on albumin dialysis (namely, Molecular Adsorbent Recirculating System; MARS) and plasma exchange.
|
28248208 |
2017 |
|
Liver Failure, Acute
|
0.010 |
Biomarker
|
disease |
BEFREE |
Twenty-seven patients with severe ALF received MARS therapy.
|
28692474 |
2017 |
|
Lung Diseases, Interstitial
|
0.010 |
Biomarker
|
group |
BEFREE |
In addition, pulmonary alveolar proteinosis is associated with mutations in CSF2RA, CSF2RB, and MARS, and specific auto-inflammatory forms of chILD implicate STING and COPA disorders.
|
29517585 |
2018 |
|
Major Depressive Disorder
|
0.020 |
Biomarker
|
disease |
BEFREE |
We analyzed data from an observational MDD cohort (Munich Antidepressant Response Signature [MARS] study, N = 1017), treated individually by psychopharmacological and psychotherapeutic means, and a multicenter, partially randomized clinical/pharmacogenomic study (Genome-based Therapeutic Drugs for Depression [GENDEP], N = 809).
|
31383853 |
2019 |